Sugi Predict

Sugi Predict / Compounds / SCHEMBL650564

SCHEMBL650564

SCHEMBL650564

COc1ccc(C(=O)OC2=C(CC=C(C)C)C(=O)[C@@]3(CC=C(C)C)C[C@H](CC=C(C)C)[C@@](C)(CCC=C(C)C)[C@]2(C(=O)C(C)C)C3=O)c(OC)c1OC

nearest known ligand 0.59

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ SIRT2 Q8IXJ6 2/20 0.59
▸ SIRT1 Q96EB6 2/20 0.59
▸ PTGES O14684 2/20 0.59
▸ SLC6A2 P23975 2/20 0.59
▸ SLC6A4 P31645 2/20 0.59
▸ SLC6A3 Q01959 2/20 0.59
▸ NR1I2 O75469 1/20 0.59
▸ CYP3A4 P08684 1/20 0.59
▸ DLAT P10515 1/20 0.59
▸ MAPT P10636 1/20 0.59
▸ SMN1; SMN2 Q16637 1/20 0.59
▸ ACHE P22303 9/20 0.49
▸ MET P08581 6/20 0.42
▸ STAT1 P42224 1/20 0.39
▸ POLL Q9UGP5 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23242189 1.00 SIRT2 (0.59) SIRT2SIRT1PTGESSLC6A2SLC6A4
SCHEMBL6135548 0.89 SIRT2 (0.61) SIRT2SIRT1PTGESSLC6A2SLC6A4
SCHEMBL6135673 0.84 SIRT2 (0.72) SIRT2SIRT1PTGESSLC6A2SLC6A4
Methoxymethane SCHEMBL7942622 0.79 SIRT2 (0.82) SIRT2SIRT1PTGESSLC6A2SLC6A4
SCHEMBL98723 0.78 SIRT2 (0.86) SIRT2SIRT1PTGESSLC6A2SLC6A4
SCHEMBL14233249 0.78 SIRT2 (0.86) SIRT2SIRT1PTGESSLC6A2SLC6A4
SCHEMBL12634392 0.78 SIRT2 (0.86) SIRT2SIRT1PTGESSLC6A2SLC6A4
SCHEMBL14577497 0.78 SIRT2 (0.86) SIRT2SIRT1PTGESSLC6A2SLC6A4
SCHEMBL21907266 0.78 SIRT2 (0.86) SIRT2SIRT1PTGESSLC6A2SLC6A4
SCHEMBL15694967 0.78 SIRT2 (0.86) SIRT2SIRT1PTGESSLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020046966-A1 TREATMENT OF ADENOCARCINOMAS WITH MAPK PATHWAY INHIBITORS KURA ONCOLOGY, INC. (US) 2020-03-05 — — WO claimed
US-20190192517-A1 TREATMENT OF SQUAMOUS CELL CARCINOMAS WITH INHIBITORS OF ERK KURA ONCOLOGY, INC. 2019-06-27 — — US claimed
EP-3471717-A1 TREATMENT OF SQUAMOUS CELL CARCINOMAS WITH INHIBITORS OF ERK Kura Oncology, Inc. (US) 2019-04-24 — — EP claimed
WO-2017222958-A1 TREATMENT OF SQUAMOUS CELL CARCINOMAS WITH INHIBITORS OF ERK KURA ONCOLOGY, INC. (US) 2017-12-28 — — WO claimed
US-20250382583-A1 ENHANCED METHODS FOR INDUCING AND MAINTAINING NAIVE HUMAN PLURIPOTENT STEM CELLS WASHINGTON UNIVERSITY ST LOUIS (US) 2025-12-18 — — US disclosed
US-12371667-B2 Enhanced methods for inducing and maintaining naive human pluripotent stem cells WASHINGTON UNIVERSITY (US) 2025-07-29 — — US disclosed
US-20220364060-A1 ENHANCED METHODS FOR INDUCING AND MAINTAINING NAIVE HUMAN PLURIPOTENT STEM CELLS WASHINGTON UNIVERSITY 2022-11-17 — — US disclosed
US-20210113555-A1 COMBINATIONS FOR THE TREATMENT OF CANCER IGNYTA, INC. (US) 2021-04-22 — — US disclosed
US-20210113555-A1 COMBINATIONS FOR THE TREATMENT OF CANCER IGNYTA, INC. (US) 2021-04-22 — — US disclosed
US-10869864-B2 Combinations for the treatment of cancer IGNYTA, INC. (US) 2020-12-22 — — US disclosed
US-10869864-B2 Combinations for the treatment of cancer IGNYTA, INC. (US) 2020-12-22 — — US disclosed
WO-2020046966-A1 TREATMENT OF ADENOCARCINOMAS WITH MAPK PATHWAY INHIBITORS KURA ONCOLOGY, INC. (US) 2020-03-05 — — WO disclosed
WO-2008109727-A1 SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2008-09-12 — — WO disclosed
WO-2008109731-A2 SUBSTITUTED PHENOXY N-ALKYLATED THIAZOLEDINEDIONE AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS JASSEN PHARMACEUTICA N.V. (BE) 2008-09-12 — — WO disclosed
US-20080221179-A1 SUBSTITUTED PHENOXY AMINOTHIAZOLONES as estrogen related receptor-alpha modulators JANSSEN PHARMACEUTICA N.V. (BE) 2008-09-11 — — US disclosed
EP-1086071-B1 HYPERFORIN DERIVATIVES, THE USE THEREOF AND FORMULATIONS CONTAINING THEM INDENA SPA (IT) 2005-10-19 — — EP disclosed
US-6656510-B2 Antidepressants INDENA S.P.A. (IT) 2003-12-02 — — US disclosed
US-20010020040-A1 Hyperforin derivatives, use thereof and formulations containing them INDENA S.P.A. (IT) 2001-09-06 — — US disclosed
EP-1086071-A1 HYPERFORIN DERIVATIVES, THE USE THEREOF AND FORMULATIONS CONTAINING THEM INDENA S.p.A. (IT) 2001-03-28 — — EP disclosed
WO-1999064388-A1 HYPERFORIN DERIVATIVES, THE USE THEREOF AND FORMULATIONS CONTAINING THEM INDENA S.P.A. (IT) 1999-12-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210113555-A1 COMBINATIONS FOR THE TREATMENT OF CANCER ROS1, NTRK3, NTRK1 SIRT2 2057/4885SIRT1 1601/4885PTGES 4816/4885
US-10869864-B2 Combinations for the treatment of cancer ROS1, NTRK3, NTRK1 SIRT2 2057/4885SIRT1 1601/4885PTGES 4816/4885
US-20010020040-A1 Hyperforin derivatives, use thereof and formulations containing them CRH, FOS, VIP SIRT2 452/4885SIRT1 231/4885PTGES 3626/4885
US-20190192517-A1 TREATMENT OF SQUAMOUS CELL CARCINOMAS WITH INHIBITORS OF ERK HRAS, TP53, MAP3K2 SIRT2 1723/4885SIRT1 2160/4885PTGES 3723/4885
US-20080221179-A1 SUBSTITUTED PHENOXY AMINOTHIAZOLONES as estrogen related receptor-alpha modulators ESR2, ESRRA, ESRRG SIRT2 4143/4885SIRT1 3336/4885PTGES 466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.